0642U CPT® code: payer coverage and prior authorization0642U appears in 3 coverage policies from Blue Cross NC, Regence, UnitedHealthcare.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Blue Cross NC | Minimal Residual Disease (MRD) AHS - M2175 | listed, no stance | Jan 1, 2026 | payer document |
| Regence | Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers (Laboratory 46) MRD | listed, no stance | Jun 1, 2026 | payer document |
| UnitedHealthcare | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions (2026T0588QQ) MRD | listed, no stance | Aug 1, 2026 | payer document |
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.